Latest news with #DARE
Yahoo
22-05-2025
- Business
- Yahoo
Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting
Studies include nearly 25,000 patients across multiple indications, showcasing the clinical impact of Signatera Breast: 8 accepted abstracts (4 oral presentations), including interim analysis from the randomized Signatera-guided interventional DARE trial; a large real-world study of metastatic treatment monitoring; and two readouts from the ISPY-2 trial Signatera Genome: Large-scale, pan-cancer performance of Signatera Genome assay GI, GU, Skin, Sarcoma: Significance of Signatera MRD and dynamics to predict recurrence, progression, and treatment response across multiple disease subtypes AUSTIN, Texas, May 22, 2025--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that data from more than 25 Signatera studies will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 30 - June 3, 2025 in Chicago, IL. Together with its collaborators, Natera will showcase the clinical utility of Signatera across 10 different cancer types. This extraordinary breadth of data includes analyses of thousands of patients, demonstrating Natera's leadership in circulating tumor DNA (ctDNA) monitoring and molecular residual disease (MRD) assessment. "The depth and breadth of Natera's research at ASCO is our most significant to date, with multiple impactful datasets in several histologies," said Alexey Aleshin, M.D., corporate chief medical officer and general manager of oncology at Natera. "The interim analysis from the DARE trial shows a possible first signal in a randomized setting that treating high-risk breast cancer patients based on Signatera results can impact clearance rates. We also look forward to sharing results on our ultra-sensitive Signatera Genome assay, along with numerous other presentations underscoring our commitment to advance the way cancer is managed." Highlights include: DARE Clinical Trial: Oral Presentation DARE is a prospective, randomized study, launched in 2021, to investigate the utility of Signatera for guiding adjuvant endocrine therapy in 585 women with high-risk, estrogen receptor-positive, HER2-negative (ER+/HER2-) breast cancer. It assesses the novel concept of "treatment on molecular recurrence" (TOMR). Patients who were Signatera-positive and imaging-negative were randomized into two arms: the standard-of-care (SOC) arm with endocrine therapy vs. the escalated arm with fulvestrant+palbociclib (CDK 4/6i). This interim analysis of 507 women and 2,208 plasma samples demonstrates the exceptional clinical performance of Signatera, and the early feasibility of both this treatment escalation approach and the TOMR trial strategy, including: Strong test sensitivity and NPV: Among patients who remained persistently Signatera-negative during screening (>400 pts), 99% remained recurrence free with a median follow up of 27.4 months. High randomization rate: Of patients who tested Signatera-positive, 73% were negative on imaging, and 93% were willing to be randomized. 2x higher ctDNA clearance: Patients in Arm A had a 2x higher rate of ctDNA clearance at 3 months vs. Arm B. Signatera Monitoring in Metastatic Breast Cancer: Oral Presentation This real-world analysis of over 600 metastatic breast cancer (mBC) patients across all disease subtypes and a wide range of therapeutic regimens (e.g., chemo, ADCs, CDK4/6) shows the utility of metastatic monitoring with Signatera: Serial ctDNA testing done at an appropriate cadence (6 weeks) can inform treatment response and clinical decisions in metastatic breast cancer. Signatera ctDNA dynamics were the strongest predictor of treatment benefit in a multivariate analysis, based on measuring time to next treatment (TTNT). Nearly 75% of patients with favorable dynamics remained on the same treatment for over 4 months, including those receiving antibody drug conjugates (ADCs) where therapy response can be challenging to evaluate on imaging. Pan-Cancer Performance of Signatera Genome: Poster Presentation Large-scale presentation of Signatera's Genome assay, analyzing more than 3,000 samples from over 300 patients across 5 major cancer types. The study includes analysis of patients with breast cancer, colorectal cancer, non-small cell lung cancer, melanoma, and renal cell carcinoma. Signatera Performance in Post-Surgical Stage I-IIIb Melanoma: Poster Presentation This study includes 197 patients and 1,681 plasma samples, tested for a median period of 2 years. This is one of the most comprehensive MRD/monitoring datasets thus far in early melanoma, demonstrating the ability of Signatera to identify patients who may benefit from escalated imaging or earlier treatment initiation. Post-surgical Signatera-positivity was the most significant predictor of recurrence free survival (RFS). In the surveillance setting, Signatera-positivity was predictive of shorter RFS (HR: 24.0, P < 0.001). Full list of oral presentations at ASCO: May 30, 2:45 PM CT | 3008 | BreastPresenter: Silver AlkhafajiCirculating tumor DNA (ctDNA) in patients with stage 2/3 HR+HER2-negative breast cancer (BC) treated with neoadjuvant endocrine therapy (NET) in the I-SPY2 endocrine optimization pilot (EOP) trial June 1, 9:45 AM CT | 4503 | GenitourinaryPresenter: Thomas Powles, MBBS, MRCP, tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA June 1, 11:30 AM CT | 3518 | GastrointestinalPresenter: Aron Bercz, Tumor DNA Provides an Early Response Assessment in Anal Squamous Cell Carcinoma Treated With Definitive Chemoradiation June 1, 4:30 PM CT | 1010 | BreastPresenter: Lajos Pusztai, M.D., DPhilCirculating tumor (ct)DNA monitoring of ER+/HER2- high-risk breast cancer (BC) during adjuvant endocrine therapy (ET) (DARE) June 1, 4:30 PM CT | 1011 | BreastPresenter: Pedram Razavi, M.D., tumor DNA (ctDNA) dynamics as a predictor of treatment response in metastatic breast cancer (mBC) June 2, 3:00 PM CT | 504 | BreastPresenter: Rita Mukhtar, nodal burden after neoadjuvant chemotherapy (NAC) with circulating tumor (ct)DNA for surgical planning: Results from the I-SPY2 trial Full list of poster presentations at ASCO: May 31, 9:00 AM CT | 11537 | SarcomaPresenter: Adie Victor, M.D., on-treatment circulating tumor (ct)DNA dynamics in response to therapy in patients with sarcoma May 31, 9:00 AM CT | 11531 | SarcomaPresenter: Maggie Zhou, assessment of response to chemotherapy via ctDNA in soft tissue sarcoma May 31, 9:00 AM CT | TPS3647 | GastrointestinalPresenter: Clara Montagut, M.D.A precision medicine trial leveraging tissue and blood-based tumor genomics to optimize treatment in resected stage III and high-risk stage II colon cancer (CC) patients (pts): The SAGITTARIUS Trial. May 31, 9:00 AM CT | 4067 | Gastrointestinal - FMIPresenter: Michele Prisciandaro, liquid biopsy in predicting recurrence in patients with operable gastroesophageal adenocarcinoma: the LIQUID study May 31, 9:00 AM CT | 4130 | GastrointestinalPresenter: Maen Abdelrahim, analysis of ctDNA and other biomarkers in patients with curatively resected Stage I-III Biliary Tract Cancer May 31, 9:00 AM CT | 3600 | GastrointestinalPresenter: Eiji Oki, of Perioperative Complications on ctDNA-based MRD Detection and Prognosis: Insights from the GALAXY Study May 31, 9:00 AM CT | 3591 | GastrointestinalPresenter: Emerik Osterlund, M.D., correlates of circulating tumor DNA (ctDNA) shedding in the INTERCEPT colorectal cancer (CRC) study May 31, 9:00 AM CT | 3597 | ColorectalPresenter: Midhun Malla, M.D., dynamics and targeted therapies associated with genetic mutations in patients with colorectal cancer May 31, 9:00 AM CT | 4073 | Esophagogastric GastricPresenter: Reetu Mukherji, analysis of over 5000 esophagogastric cancers June 1, 9:00 AM CT | 9574 | Merkel Cell CarcinomaPresenter: Joshua Elbridge ChanComparison of surveillance circulating tumor DNA and merkel polyomavirus antibody titer for detection of merkel cell carcinoma recurrence June 1, 9:00 AM CT | 9571 | MelanomaPresenter: George Ansstas, ctDNA monitoring for post-surgical molecular residual disease in patients with stage I-IIIb melanoma June 1, 9:00 AM CT | 9523 | MelanomaPresenter: Caroline BurkeyCirculating tumor DNA (ctDNA) dynamics during anti-PD-1 based therapy to predict clinical outcomes in advanced stage melanoma: A multicenter retrospective study. June 1, 9:00 AM CT | 9584 | MelanomaPresenter: Vincent The-Luc MaSensitivity of circulating tumor DNA (ctDNA) for disease recurrence or relapse in melanoma patients June 1, 9:00 AM CT | 5563 | GynecologicalPresenter: Jung-Yun Lee, M.D., monitoring in participants with ovarian cancer treated with neoadjuvant pembrolizumab (pembro) plus chemotherapy (chemo) with or without the anti–immunoglobulin-like transcript 4 (ILT4) monoclonal antibody MK-4830 June 2, 9:00 AM CT | 4565 | GenitourinaryPresenter: Adanma Ayanambakkam, of Tumor-Informed ctDNA-based Molecular Residual Disease (MRD) with Clinical Outcomes for Upper Tract Urothelial Cancer (UTUC) June 2, 9:00 AM CT | 4602 | GenitourinaryPresenter: Ilana EpsteinCorrelation of circulating tumor DNA (ctDNA) dynamics with clinical response in muscle-invasive bladder cancer (MIBC) patients (pts) undergoing trimodality therapy (TMT) June 2, 9:00 AM CT | 4560 | GenitourinaryPresenter: Kevin R. Reyes, BSCirculating tumor DNA (ctDNA) monitoring in patients (pts) with advanced urothelial carcinoma (aUC) treated with Enfortumab Vedotin +/- Pembrolizumab (EVP) June 2, 9:00 AM CT | TPS620 | BreastPresenter: Michail Ignatiadis, M.D., Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA) June 2, 9:00 AM CT | 581 | BreastPresenter: Julia Foldi, M.D., circulating tumor DNA (ctDNA) monitoring in early-stage, HR+/HER2-, invasive lobular carcinoma (ILC) of the breast and impact on clinical outcomes June 2, 9:00 AM CT | 560 | BreastPresenter: Marla Lipsyc-Sharf, of circulating tumor DNA (ctDNA) testing for molecular surveillance in early-stage breast cancer (eBC) June 2, 9:00 AM CT | 612 | BreastPresenter: Mei Wei, M.D.I-SPY2 endocrine optimization pilot (EOP): Neoadjuvant lasofoxifene (Laso) in molecularly selected patients with hormone receptor positive (HR+)/HER2 negative (HER2-) stage 2/3 breast cancer (BC) June 2, 1:30 PM CT | 3142 | PancancerPresenter: Mridula George, performance of Signatera Genome assay in a cohort of patients (pts) with solid tumors June 2, 1:30 PM CT | 3048 | GastrointestinalPresenter: John Paul Y.C. Shen, of a methylation-based, tissue-free test for the detection of molecular residual disease by circulating tumor DNA About Signatera Signatera is a personalized, tumor-informed, molecular residual disease test for patients previously diagnosed with cancer. Custom-built for each individual, Signatera uses circulating tumor DNA to detect and quantify cancer left in the body, identify recurrence earlier than standard of care tools, and help optimize treatment decisions. The test is available for clinical and research use and has coverage by Medicare across a broad range of indications. Signatera has been clinically validated across multiple cancer types and indications, with published evidence in more than 100 peer-reviewed papers. About Natera Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are supported by more than 250 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy and performance of our tests, or of the benefits of our tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera's recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at and View source version on Contacts Investor Relations: Mike Brophy, CFO, Natera, Inc., investor@ Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
22-05-2025
- Business
- Business Wire
Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting
AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that data from more than 25 Signatera studies will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 30 - June 3, 2025 in Chicago, IL. Together with its collaborators, Natera will showcase the clinical utility of Signatera across 10 different cancer types. This extraordinary breadth of data includes analyses of thousands of patients, demonstrating Natera's leadership in circulating tumor DNA (ctDNA) monitoring and molecular residual disease (MRD) assessment. 'The depth and breadth of Natera's research at ASCO is our most significant to date, with multiple impactful datasets in several histologies,' said Alexey Aleshin, M.D., corporate chief medical officer and general manager of oncology at Natera. 'The interim analysis from the DARE trial shows a possible first signal in a randomized setting that treating high-risk breast cancer patients based on Signatera results can impact clearance rates. We also look forward to sharing results on our ultra-sensitive Signatera Genome assay, along with numerous other presentations underscoring our commitment to advance the way cancer is managed.' Highlights include: DARE Clinical Trial: Oral Presentation DARE is a prospective, randomized study, launched in 2021, to investigate the utility of Signatera for guiding adjuvant endocrine therapy in 585 women with high-risk, estrogen receptor-positive, HER2-negative (ER+/HER2-) breast cancer. It assesses the novel concept of 'treatment on molecular recurrence' (TOMR). Patients who were Signatera-positive and imaging-negative were randomized into two arms: the standard-of-care (SOC) arm with endocrine therapy vs. the escalated arm with fulvestrant+palbociclib (CDK 4/6i). This interim analysis of 507 women and 2,208 plasma samples demonstrates the exceptional clinical performance of Signatera, and the early feasibility of both this treatment escalation approach and the TOMR trial strategy, including: Strong test sensitivity and NPV: Among patients who remained persistently Signatera-negative during screening (>400 pts), 99% remained recurrence free with a median follow up of 27.4 months. High randomization rate: Of patients who tested Signatera-positive, 73% were negative on imaging, and 93% were willing to be randomized. 2x higher ctDNA clearance: Patients in Arm A had a 2x higher rate of ctDNA clearance at 3 months vs. Arm B. Signatera Monitoring in Metastatic Breast Cancer: Oral Presentation This real-world analysis of over 600 metastatic breast cancer (mBC) patients across all disease subtypes and a wide range of therapeutic regimens (e.g., chemo, ADCs, CDK4/6) shows the utility of metastatic monitoring with Signatera: Serial ctDNA testing done at an appropriate cadence (6 weeks) can inform treatment response and clinical decisions in metastatic breast cancer. Signatera ctDNA dynamics were the strongest predictor of treatment benefit in a multivariate analysis, based on measuring time to next treatment (TTNT). Nearly 75% of patients with favorable dynamics remained on the same treatment for over 4 months, including those receiving antibody drug conjugates (ADCs) where therapy response can be challenging to evaluate on imaging. Pan-Cancer Performance of Signatera Genome: Poster Presentation Large-scale presentation of Signatera's Genome assay, analyzing more than 3,000 samples from over 300 patients across 5 major cancer types. The study includes analysis of patients with breast cancer, colorectal cancer, non-small cell lung cancer, melanoma, and renal cell carcinoma. Signatera Performance in Post-Surgical Stage I-IIIb Melanoma: Poster Presentation This study includes 197 patients and 1,681 plasma samples, tested for a median period of 2 years. This is one of the most comprehensive MRD/monitoring datasets thus far in early melanoma, demonstrating the ability of Signatera to identify patients who may benefit from escalated imaging or earlier treatment initiation. Post-surgical Signatera-positivity was the most significant predictor of recurrence free survival (RFS). In the surveillance setting, Signatera-positivity was predictive of shorter RFS (HR: 24.0, P < 0.001). Full list of oral presentations at ASCO: May 30, 2:45 PM CT | 3008 | Breast Presenter: Silver Alkhafaji Circulating tumor DNA (ctDNA) in patients with stage 2/3 HR+HER2-negative breast cancer (BC) treated with neoadjuvant endocrine therapy (NET) in the I-SPY2 endocrine optimization pilot (EOP) trial June 1, 9:45 AM CT | 4503 | Genitourinary Presenter: Thomas Powles, MBBS, MRCP, M.D. Circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA June 1, 11:30 AM CT | 3518 | Gastrointestinal Presenter: Aron Bercz, M.D. Circulating Tumor DNA Provides an Early Response Assessment in Anal Squamous Cell Carcinoma Treated With Definitive Chemoradiation June 1, 4:30 PM CT | 1010 | Breast Presenter: Lajos Pusztai, M.D., DPhil Circulating tumor (ct)DNA monitoring of ER+/HER2- high-risk breast cancer (BC) during adjuvant endocrine therapy (ET) (DARE) June 1, 4:30 PM CT | 1011 | Breast Presenter: Pedram Razavi, M.D., Ph.D. Circulating tumor DNA (ctDNA) dynamics as a predictor of treatment response in metastatic breast cancer (mBC) June 2, 3:00 PM CT | 504 | Breast Presenter: Rita Mukhtar, M.D. Predicting nodal burden after neoadjuvant chemotherapy (NAC) with circulating tumor (ct)DNA for surgical planning: Results from the I-SPY2 trial Full list of poster presentations at ASCO: May 31, 9:00 AM CT | 11537 | Sarcoma Presenter: Adie Victor, M.D., M.S. Early on-treatment circulating tumor (ct)DNA dynamics in response to therapy in patients with sarcoma May 31, 9:00 AM CT | 11531 | Sarcoma Presenter: Maggie Zhou, M.D. Early assessment of response to chemotherapy via ctDNA in soft tissue sarcoma May 31, 9:00 AM CT | TPS3647 | Gastrointestinal Presenter: Clara Montagut, M.D. A precision medicine trial leveraging tissue and blood-based tumor genomics to optimize treatment in resected stage III and high-risk stage II colon cancer (CC) patients (pts): The SAGITTARIUS Trial. May 31, 9:00 AM CT | 4067 | Gastrointestinal - FMI Presenter: Michele Prisciandaro, M.D. Tumor-informed liquid biopsy in predicting recurrence in patients with operable gastroesophageal adenocarcinoma: the LIQUID study May 31, 9:00 AM CT | 4130 | Gastrointestinal Presenter: Maen Abdelrahim, M.D. Real-world analysis of ctDNA and other biomarkers in patients with curatively resected Stage I-III Biliary Tract Cancer May 31, 9:00 AM CT | 3600 | Gastrointestinal Presenter: Eiji Oki, Ph.D. Impact of Perioperative Complications on ctDNA-based MRD Detection and Prognosis: Insights from the GALAXY Study May 31, 9:00 AM CT | 3591 | Gastrointestinal Presenter: Emerik Osterlund, M.D., Ph.D. Biologic correlates of circulating tumor DNA (ctDNA) shedding in the INTERCEPT colorectal cancer (CRC) study May 31, 9:00 AM CT | 3597 | Colorectal Presenter: Midhun Malla, M.D., M.S. ctDNA dynamics and targeted therapies associated with genetic mutations in patients with colorectal cancer May 31, 9:00 AM CT | 4073 | Esophagogastric Gastric Presenter: Reetu Mukherji, M.D. Exome analysis of over 5000 esophagogastric cancers June 1, 9:00 AM CT | 9574 | Merkel Cell Carcinoma Presenter: Joshua Elbridge Chan Comparison of surveillance circulating tumor DNA and merkel polyomavirus antibody titer for detection of merkel cell carcinoma recurrence June 1, 9:00 AM CT | 9571 | Melanoma Presenter: George Ansstas, M.D. Longitudinal ctDNA monitoring for post-surgical molecular residual disease in patients with stage I-IIIb melanoma June 1, 9:00 AM CT | 9523 | Melanoma Presenter: Caroline Burkey Circulating tumor DNA (ctDNA) dynamics during anti-PD-1 based therapy to predict clinical outcomes in advanced stage melanoma: A multicenter retrospective study. June 1, 9:00 AM CT | 9584 | Melanoma Presenter: Vincent The-Luc Ma Sensitivity of circulating tumor DNA (ctDNA) for disease recurrence or relapse in melanoma patients June 1, 9:00 AM CT | 5563 | Gynecological Presenter: Jung-Yun Lee, M.D., Ph.D. ctDNA monitoring in participants with ovarian cancer treated with neoadjuvant pembrolizumab (pembro) plus chemotherapy (chemo) with or without the anti–immunoglobulin-like transcript 4 (ILT4) monoclonal antibody MK-4830 June 2, 9:00 AM CT | 4565 | Genitourinary Presenter: Adanma Ayanambakkam, M.D. Association of Tumor-Informed ctDNA-based Molecular Residual Disease (MRD) with Clinical Outcomes for Upper Tract Urothelial Cancer (UTUC) June 2, 9:00 AM CT | 4602 | Genitourinary Presenter: Ilana Epstein Correlation of circulating tumor DNA (ctDNA) dynamics with clinical response in muscle-invasive bladder cancer (MIBC) patients (pts) undergoing trimodality therapy (TMT) June 2, 9:00 AM CT | 4560 | Genitourinary Presenter: Kevin R. Reyes, BS Circulating tumor DNA (ctDNA) monitoring in patients (pts) with advanced urothelial carcinoma (aUC) treated with Enfortumab Vedotin +/- Pembrolizumab (EVP) June 2, 9:00 AM CT | TPS620 | Breast Presenter: Michail Ignatiadis, M.D., Ph.D. EORTC-2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA) June 2, 9:00 AM CT | 581 | Breast Presenter: Julia Foldi, M.D., Ph.D. Serial circulating tumor DNA (ctDNA) monitoring in early-stage, HR+/HER2-, invasive lobular carcinoma (ILC) of the breast and impact on clinical outcomes June 2, 9:00 AM CT | 560 | Breast Presenter: Marla Lipsyc-Sharf, M.D. Cadence of circulating tumor DNA (ctDNA) testing for molecular surveillance in early-stage breast cancer (eBC) June 2, 9:00 AM CT | 612 | Breast Presenter: Mei Wei, M.D. I-SPY2 endocrine optimization pilot (EOP): Neoadjuvant lasofoxifene (Laso) in molecularly selected patients with hormone receptor positive (HR+)/HER2 negative (HER2-) stage 2/3 breast cancer (BC) June 2, 1:30 PM CT | 3142 | Pancancer Presenter: Mridula George, M.D. Clinical performance of Signatera Genome assay in a cohort of patients (pts) with solid tumors June 2, 1:30 PM CT | 3048 | Gastrointestinal Presenter: John Paul Y.C. Shen, M.D. Development of a methylation-based, tissue-free test for the detection of molecular residual disease by circulating tumor DNA About Signatera Signatera is a personalized, tumor-informed, molecular residual disease test for patients previously diagnosed with cancer. Custom-built for each individual, Signatera uses circulating tumor DNA to detect and quantify cancer left in the body, identify recurrence earlier than standard of care tools, and help optimize treatment decisions. The test is available for clinical and research use and has coverage by Medicare across a broad range of indications. Signatera has been clinically validated across multiple cancer types and indications, with published evidence in more than 100 peer-reviewed papers. About Natera Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are supported by more than 250 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy and performance of our tests, or of the benefits of our tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in 'Risk Factors' in Natera's recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at and
Yahoo
19-05-2025
- Business
- Yahoo
Wall PIE and Singapore Polytechnic Expand Space Engineering Education Through Landmark 10-Year MOU, as Singaporean Prodigy Elizabeth Ng Breaks Barriers in Global Space Arena
SINGAPORE, May 19, 2025 /PRNewswire/ --Wall PIE Pte Ltd, a trailblazing Singaporean company at the forefront of space and AI education, has announced a historic 10-year Memorandum of Understanding (MOU) with Singapore Polytechnic to expand its Spacecraft Engineering elective program. This milestone initiative cements a long-term partnership that promises to shape the future of aerospace and artificial intelligence talent in Singapore and beyond. The announcement comes amid growing regional momentum in space innovation, and closely follows an extraordinary achievement by 11-year-old Elizabeth Ng—a shining graduate of Wall PIE's Space Juniors Program—who has been accepted into Elon Musk's prestigious Space School with a full scholarship. Elizabeth is now collaborating with Russia's Roscosmos to launch an AI-powered optical satellite, marking a new chapter in youth-led aerospace advancement. A Bold Leap in Aerospace Education Under the MOU, Wall PIE will co-develop and deliver comprehensive Space Engineering electives across Singapore Polytechnic's Diploma in Aeronautical Engineering (DARE) and Diploma in Aerospace Electronics (DASE) programs. The initiative, which began with a pilot batch of classes in 2024, has seen tremendous demand and will now expand into multiple sessions per academic year, offering more students access to future-forward aerospace training. Key areas of collaboration include: Development of specialized Space Engineering modules integrated into SP's academic curriculum Internships and industry attachments for DARE and DASE students at Wall PIE and partner facilities Co-supervision of final year projects, particularly in spacecraft systems, AI integration, and orbital design Joint applied research and development projects, such as satellite prototyping, AI payload integration, and earth observation technologies Continuing Education & Training (CET) for adult learners and educators in the space sector Sponsorship of scholarships, awards, and innovation grants to support aspiring engineers and technologists Support for workshops, career talks, and seminars, including global speakers and space tech demonstrations Faculty exchange and consultancy programs, enabling academic staff to work directly on Wall PIE's ongoing projects, including satellite AI modeling and LEO satellite network optimization Jesslyn Wong, Founder and CEO of Wall PIE, emphasized the strategic significance of the partnership: > "The age of AI and Space Tech is here. ASEAN's young leaders must be bold and competent to remain relevant in the global race. Through our collaboration with Singapore Polytechnic, we're investing in the future minds who will not only operate but lead space missions. This is our mission—to democratize access to the stars." Youth at the Helm: Elizabeth Ng's Historic Space Feat Wall PIE's commitment to nurturing young talent is exemplified by Elizabeth Ng Ziqi who continues to astonish global observers with her scientific accomplishments. At only 11, Elizabeth has become the first Singaporean student accepted into Elon Musk's elite Space School, earning a fully sponsored seat thanks to her advanced work in AI and aerospace systems. In partnership with Roscosmos, Elizabeth is now preparing for the launch of a real optical Earth observation satellite, equipped with a custom-designed large language model (LLM) chip that enables onboard real-time image processing and data interpretation. The AI payload, co-developed with Wall PIE and Tabernacle Health Group, will drastically reduce latency in Earth-to-space communication and enable autonomous decision-making for orbital platforms. Elizabeth previously made headlines in 2024 when her AI-generated song was broadcast from the International Space Station, marking a creative and technological first for Singapore. Her current project pushes even further into technical domains, fusing edge computing, space optics, and deep learning into a singular low-earth orbit (LEO) platform. Wall PIE's Technological Edge: Satellite-Based AI with BaoBao LLM As part of their broader R&D roadmap, Wall PIE also announced the impending launch of their proprietary BaoBao LLM—a lightweight, locally runnable AI model which is less than a hundred lines of code designed for space applications. Unlike traditional cloud-based models, BaoBao is optimized to run directly on an SDRAM card, making it exceptionally suited for edge deployments in orbit. The model will perform in-situ image recognition and anomaly detection aboard nanosatellites, reducing reliance on ground stations. Wall PIE plans to incorporate BaoBao into its student-led satellite missions, offering Singaporean undergraduates a chance to participate in real satellite deployments, complete with AI payload development, integration, and testing. About Wall PIE Pte Ltd Wall PIE is a Singapore-based aerospace and artificial intelligence education company committed to democratizing access to space technology. Through its award-winning education programs—including the Space Juniors Program, AI Payload Labs, and Orbital Engineering Studio—Wall PIE equips youth and young professionals with the skills to design, prototype, and launch real-world space missions. The company's partnerships span local institutions, global space agencies, and private sector innovators, creating a powerful bridge between classroom theory and cosmic exploration. About Singapore Polytechnic Established in 1954, Singapore Polytechnic is Singapore's first polytechnic and a leader in applied learning. With a strong emphasis on innovation and industry collaboration, SP nurtures students to become versatile professionals equipped with future-ready skills. The institution offers more than 30 full-time diploma courses and a wide range of Continuing Education & Training programs across diverse industries. Related News: Elizabeth Ng Broadcasts AI-Generated Song from ISS #SpaceEducation #SingaporeInnovation #WallPIE #AIInSpace #YouthInSTEM #ElizabethNg #SpaceSchool #SPPoly #BaoBaoLLM View original content to download multimedia: SOURCE Wall PIE Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11-05-2025
- Yahoo
Jasper County Sheriff's Office highlights safety at annual event
JASPER CO., Mo. — It was a day full of fun and safety for Jasper County residents. The Jasper County Sheriff's Office hosted its annual 'Community Safety Day' outside the office. More than 200 attendees showed up this year, learning firsthand some of the things the Sheriff's office does every day. From 10:00 a.m. to 1:00 p.m., loads of live demonstrations filled the area, including the SWAT team, K-9's and the horseback posse. Attendees also enjoyed free food from the grill, face painting, a bounce house, and snow cones. 'It's just kind of showing a little bit of what we do. And, you know, part of what we do, we need the community's help. And so it helps to interact with them, get to know each other. So they feel more comfortable calling us and interacting with us,' said Derek Walrod, Jasper County Sheriff's Office Chief Deputy. D.A.R.E., Children's Haven, and the Jasper County Health Department also set up booths today to share information with the community. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
02-05-2025
- Health
- Yahoo
Lenoir County marks first DARE class graduation of 2025
KINSTON, N.C. (WNCT) — After more than 15 years, the Lenoir County Sheriff's Office announced the first Drug Abuse Resistance Education (DARE) graduation Class of 2025. Students from Southwood Elementary School completed a 10-week program and were awarded certificates of completion Friday, May 2, 2025, by Principal Wendy Piro, LCSO Maj. Larry Greene, Sgt. Josh Garner, and Deputy Breanna McWilliams. The DARE program is now known as 'Keepin` it Real.' It focuses on students learning about drug prevention, decision-making and leadership skills. Six out of the nine Lenoir County Elementary Schools are currently enrolled in this program.'The students focused on not only how to say no to drugs but also building their self-confidence,' Southwood Elementary School Principal, Wendy Piro said. 'She talked about one of things was helping our students say no to vapes and I know from being at the middle school that is a huge issue our students now face. So, equipping our fifth-grade students with those skills as they go to middle school is very helpful.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
